Octreotide is a synthetic peptide analog of somatostatin with the same pharmacologic effects. Its primary advantages over somatostatin are a longer half-life in the circulation, a higher potency, and good bioavailability after subcutaneous administration.\(^1\)-\(^3\) The half-life of somatostatin is 2–3 minutes compared with 1–2 h for octreotide. Consequently, octreotide has largely supplanted somatostatin as a therapeutic agent for several diseases. The effects of somatostatin and octreotide occur as a result of binding to G protein receptors found throughout the body, including the gastrointestinal tract, pancreas, and the central nervous system.\(^4\) Octreotide decreases the production of gastrointestinal peptides, such as gastrin, secretin, gastric inhibitory peptide, cholecystokinin, neurotensin, motilin, and pancreatic polypeptide.\(^3,5,6\) This reduction in gastrointestinal peptides leads to multiple pharmacologic alterations in intestinal function.

The experience with octreotide for the treatment of gastrointestinal disorders in children is limited, with the vast majority of data in the form of case reports, small case series, or reviews of these reports.\(^7-9\) We report our experience with the use of octreotide as primary or adjunctive therapy for infants and children with multiple gastrointestinal disorders.

**PATIENTS AND METHODS**

A pharmacy database was used to identify all patients up to 18 years of age, who received octreotide (Novartis Pharmaceutical, Montreal, Canada) at the Alberta Children’s Hospital in Calgary, from January 1998 to December 2004. Patients who received octreotide as primary or adjunctive therapy for gastrointestinal disorders were included.
Exclusion criterion was the use of octreotide as a primary therapy for nongastrointestinal endocrine disorders. A retrospective review of medical records was performed and demographic data were collected. These included age, weight, gender, and underlying medical condition necessitating octreotide use. Octreotide dosing, duration of use, mode of administration (intermittent or continuous), route of administration (intravenous (IV) or subcutaneous (SC)) and adverse effects attributed to octreotide were also recorded.

The effectiveness of octreotide was evaluated by the assessment of certain measurable variables based on the indication for its use. In patients with gastrointestinal bleeding, packed red blood cell requirement during the 24-h period before and 48-h period following administration of octreotide was obtained. Cessation of bleeding was defined as the absence of bleeding for 48 h after the administration of octreotide with stabilization of vital signs and hemoglobin. Rebleeding was defined as the recurrence of hematemesis, bright red blood in the nasogastric tube, rectum, or melena with hemoglobin drop of 2 gm/dL and deterioration of vital signs after cessation of or attempt to wean octreotide. Failure of therapy was defined as the persistence of bleeding during octreotide therapy. In patients with pancreatic disorders, data were collected based on imaging (ultrasound or computed tomography of abdomen) measurements of pseudocyst size, abdominal drain of pancreatic ascites, or serum lipase levels before and during octreotide administration. For patients with chronic diarrhea, the amount of stool output and total fluid intake were obtained before and during octreotide administration. For patients with chronic diarrhea, the amount of stool output and total fluid intake were obtained before and during octreotide therapy. In cases of chylothorax, data were collected about chest drain output before and during octreotide administration. For the patient with dumping syndrome, symptomatic response to octreotide therapy was evaluated.

Blood requirements before and during octreotide therapy were compared by paired t-test. Values are expressed as mean±standard deviation. The study was approved by the institutional review board.

RESULTS

Octreotide was administered to 26 patients. Five of 26 patients were excluded: 3 patients with hyperinsulinemic hypoglycemia and 2 with acromegaly. A total of 21 patients aged 1 month to 13 years (5±4.5 years) were included (9 girls, 12 boys). The indications of octreotide use included massive gastrointestinal bleeding (n=11), complications of pancreatitis (n=4), chylothorax postcardiac surgery (n=3), chronic diarrhea (n=2), and dumping syndrome (n=1) [Table 1].

The causes of gastrointestinal bleeding included esophageal varices (n=4), gastric varix (n=1), portal hypertensive gastropathy (n=2), typhilitis (n=1), Meckel’s diverticulum (n=1), and indefinite source (n=2). The mean hemoglobin drop at presentation was 3.31±0.45 g/dL. The mean of the initial octreotide bolus administered was 2.2±1.0 µg/kg, and the mean continuous infusion was 2.2±1.0 µg/kg/h. Octreotide infusion rate was tapered by half for 24 h and was stopped when there was no active bleeding. Bleeding ceased in 8 patients (72%) and those with esophageal varices underwent esophageal sclerotherapy or banding once stabilized.

Patients 1, 2, and 9 failed octreotide therapy (28%). Patient 1 underwent a negative upper endoscopy and colonoscopy. Meckel’s scan was positive and a Meckel’s diverticulum was resected. Nonsteroidal anti-inflammatory drug use for joint pains in patient 2 raises the possibility of proximal small intestinal ulceration or erosion in view of negative upper endoscopy. This child with chronic renal failure did not respond to IV proton pump inhibitor and died 48 h after admission due to cardiac arrhythmia, hyperkalemia, and pulmonary edema. Patient 9 had endstage liver disease secondary to prolonged total parenteral nutrition (TPN) use for short gut, with severe coagulopathy unresponsive to vitamin K injections or fresh frozen plasma and bled persistently despite continuous octreotide infusion for 14 days. The family preferred palliative management rather than the option of combined liver and bowel transplantation.

Bleeding recurred in patients 6, 7, 8, and 10 (50%). Six months after the first gastrointestinal bleed, patient 6 experienced recurrent bleeding esophageal varices with no response to octreotide, and needed emergent portacaval shunt with no recurrence of bleeding. Initially patient 7 with aplastic anemia developed a massive gastrointestinal bleed with oozing from the small intestine that was not controlled with blood products. Octreotide therapy was instituted as outlined in Table 1 and bleeding ceased in 24 h. Therapy was discontinued at 72 h. Nine days after discontinuation of octreotide, massive lower gastrointestinal bleeding recurred that did not respond to reinstitution of octreotide infusion at 2 µg/kg/h for 3 days and then 4 µg/kg/h for 2 days. He developed signs of typhilitis, underwent a right hemicolecetomy and had no recurrence of gastrointestinal bleeding. The resected specimen demonstrated extensive cecal necrosis and ulceration. Patient 8 had recurrence of esophageal variceal bleed on two occasions, one month apart. The second bleed occurred two months after the first one and responded to reinstitution of octreotide bolus at 2 µg/kg and 2 µg/kg/h for 3 days. In patient 10, 2 attempts to wean octreotide to 1 µg/kg/hr were associated with recurrence of bleeding. Injection of gastric varix with cyanoacrylate was performed on day 7 of octreotide therapy and octreotide was successfully weaned. Patients 4, 5, 6, and 8 had sclerotherapy.
### Table 1: Clinical and therapeutic characteristics of patients with gastrointestinal disorders on octreotide therapy

| Patient | Age (year) | Sex | Indication                                                                 | Dose                                      | Duration (day) |
|---------|------------|-----|-----------------------------------------------------------------------------|-------------------------------------------|----------------|
| 1       | 5          | M   | Massive lower gastrointestinal bleeding                                      | 2 µg/kg IV; 2 µg/kg/h IV continuous infusion | 2              |
| 2       | 10.5       | F   | Massive upper gastrointestinal bleeding, chronic renal failure on nonsteroidal anti-inflammatory drug, negative upper endoscopy | 2 µg/kg IV bolus, 2 µg/kg/h IV continuous infusion for one day and then 4 µg/kg/h for one day | 2              |
| 3       | 3          | F   | Massive lower gastrointestinal bleeding, intestinal dysmotility, TPN cholestasis, portal hypertension, negative upper endoscopy and colonoscopy | 2 µg/kg IV bolus, 2 µg/kg/h IV continuous infusion | 2              |
| 4       | 1.2        | F   | Esophageal varices, prehepatic portal vein thrombosis                        | 2 µg/kg IV bolus, 2 µg/kg/h IV continuous infusion | 3              |
| 5       | 0.5        | M   | Esophageal varices, post Kasai procedure for biliary atresia                 | 5 µg/kg IV bolus, 5 µg/kg/h IV continuous infusion | 5              |
| 6       | 12         | M   | Esophageal varices, congenital hepatic fibrosis                             | 2 µg/kg/h IV continuous infusion          | 3              |
| 7       | 8          | F   | Massive lower gastrointestinal bleeding, typhilitis, aplastic anemia, unstable for intervention | 2 µg/kg IV bolus, 2 µg/kg/h IV continuous infusion | 3              |
| 8       | 6          | M   | Esophageal varices, sclerosing cholangitis with ulcerative colitis          | 1 µg/kg bolus, 1 µg/kg/h IV continuous IV infusion | 3              |
| 9       | 0.7        | M   | Massive lower and upper gastrointestinal bleeding, short gut (gastroscisis and volvulus), prolonged TPN-related decompensated cirrhosis, portal gastropathy and negative colonoscopy | 2 µg/kg/h IV continuous infusion          | 14             |
| 10      | 13         | F   | Gastric varix, chronic renal failure, portal vein thrombosis secondary to pancreatitis | 2 µg/kg IV bolus, 2 µg/kg/h IV continuous infusion | 17             |
| 11      | 0.8        | M   | Upper and lower gastrointestinal bleeding, short gut (surgery for multiple intestinal atresia), prolonged TPN-related cirrhosis with portal gastropathy | 2 µg/kg IV bolus, 2 µg/kg/h IV continuous infusion | 4              |
| 12      | 4          | F   | Traumatic pancreatitis, pseudocyst (5 × 6 cm), pancreatic ascites, enteropancreatic fistula. No response to 10 days of bowel rest and TPN. | 10.5 µg/kg/d SC b.i.d.                     | 14             |
| 13      | 9          | M   | Traumatic pancreatitis, pancreatic ascites, severe abdominal pain. No response to one week of bowel rest and TPN. | 2 µg/kg/d IV b.i.d.                       | 14             |
| 14      | 13         | F   | Severe pancreatitis, one week after portosystemic shunt surgery for portal vein thrombosis, pancreatic pseudocyst (5 × 6 cm), no response to five weeks of TPN | 7.5 µg/kg/d SC TID                        | 7              |
| 15      | 9          | M   | Pancreatitis, infected pseudocyst (5 × 8 cm) with compression effects on common bile duct (jaundice), septic shock | 2 µg/kg/d SC t.i.d.                       | 28             |
| 16      | 0.5        | M   | Right chylothorax, tricuspid atresia, 2 weeks post–Glenn-bidirectional shunt surgery. No improvement on enteral portagen and TPN for 1 week | 8.3 µg/kg/d SC b.i.d.                     | 7              |
| 17      | 4.5        | F   | Right chylothorax, 3 weeks post-Fontan procedure for pulmonary atresia, common ventricle and heterotaxia. No improvement on TPN for 1 week | 10 µg/kg/d SC b.i.d.                      | 14             |
| 18      | 2.5        | M   | Right chylothorax, 3 weeks post-Fontan procedure. No improvement on portagen and TPN for 10 days | 14 µg/kg/d SC b.i.d.                      | 21             |
| 19      | 0.8        | M   | Congenital intestinal epithelial dysplasia with chronic secretory diarrhea | 20 µg/kg/d SC TID                        | 420            |
| 20      | 0.1        | F   | Short gut (18 cm of small intestine) secondary to necrotising enterocolitis with excessive stoma output | 4 µg/kg/d SC b.i.d.                       | 240            |
| 21      | 20         | M   | Gastroesophageal reflux disease, dumping syndrome two months post fundoplication. No response to trial of continuous gastrostomy tube feeding | 2 µg/kg/d SC b.i.d.                       | 60             |

M: Male, F: Female, IV: Intravenous, SC: Subcutaneous, TPN: Total parenteral nutrition
of esophageal varices on day 1 of octreotide. Figure 1 demonstrates a significant reduction in packed red blood cell requirement from 23±9 mL/kg before treatment to 8±15 mL/kg after treatment (P<0.01 by paired t test).

Four patients [Table 1, patients 12–15] developed pancreatic pseudocysts and/or ascites within 3 weeks after onset of severe pancreatitis. Pancreatic pseudocysts in patients 12, 14, and 15 resolved completely over a mean duration of 12±2 days and did not recur. Serum lipase decreased from 7682±9064 IU/L (Normal, <60 IU/L) to 347±263 IU/L 2 weeks after initiation of octreotide therapy. In addition, patient 12 developed watery diarrhea with a stool lipase level >3300 IU/L, thought to be due to an enteropancreatic fistula. The diarrhea resolved 3 days after initiation of octreotide therapy. Patient 15 had endoscopic transgastric drainage of infected pseudocyst on day 1 of octreotide therapy. Culture of cyst fluid grew pseudomonas organisms treated by IV antibiotics.

Patients 16, 17, and 18 [Table 1] each developed a chylothorax that required placement of a chest tube within 2–3 weeks after cardiac surgery. The resolution of chylothorax was confirmed on chest X-ray. Figure 2 demonstrates the dramatic reduction in chest tube drainage after administration of octreotide in each child.

Patient 19, an infant with intractable diarrhea due to epithelial dysplasia, displayed a reduction of stool output from a range of 53–73 mL/kg/d prior to octreotide therapy to 25 and 15 mL/kg/d by days 30 and 90 of octreotide therapy, respectively. TPN requirement progressively declined from 85% to 70% and 50% of total daily caloric intake by days 30 and 90 of octreotide therapy, respectively. Fourteen months after initiating octreotide therapy, this patient was receiving 70% of total daily intake by enteral feeds and she grew continuously along 5th centile for both weight and height. Patient 20, a child with short gut after necrotizing enterocolitis, demonstrated a progressive decrease in stool output from 85–105 mL/kg/d to 55 (day 30) and 35 mL/kg/day (day 90) after initiating octreotide therapy. In parallel to the reduction of stool output, TPN requirement decreased from 100% to 80% and 50% of total daily caloric intake at days 30 and 90 of octreotide therapy, respectively. Weight was maintained along the 20th centile.

Patient 21 [Table 1] presented with symptoms suggestive of dumping syndrome that developed 2 months postfundoplication for gastroesophageal reflux disease. Bolus feeding caused a rise of serum glucose from 5.4 to 16 mmol/L at 30 min followed by a dramatic reduction to 2 mmol/L at 90 min postfeeding. The glucose reduction was associated with onset of lethargy, sweating, and diarrhea. Failure to respond to a continuous feeding led to a trial of octreotide, with alleviation of the symptoms within a week.

Side effects of octreotide developed in 4 of 21 patients. Patient 7 suffered bradycardia that progressed into ventricular fibrillation, and was successfully resuscitated. Electrocardiography demonstrated prolonged corrected Q–T interval (Q–Tc) of 0.46–0.48 second (normal, <0.45 second). Echocardiogram and serum electrolytes were normal. At that point, the patient was receiving octreotide at 4 µg/kg/h in an attempt to control lower gastrointestinal bleeding. The dose was reduced to 1 µg/kg/h and the patient was started...
Octreotide in children

of endoscopic sclerotherapy/banding and octreotide is allowed them to be managed with banding or for 10 days. The insulin was discontinued with no recurrence of hyperglycemia. Patient 20 suffered recurrent hypoglycemia (serum glucose <2.5 mmol/L) 5 months after starting octreotide therapy. Hormonal analysis at the time of hypoglycemia revealed an abnormally low response of serum growth hormone of 1.1 mg/L (Normal, 0.2–7 mg/L), normal serum cortisol, adrenocorticotropic, and thyroid stimulating hormone, and a normally suppressed serum insulin at <21 pmol/L. Provocative growth hormone testing using IV arginine revealed an abnormally low serum growth hormone of 1.2 mg/L (Normal, >3 mg/L). The hypoglycemic episodes responded to growth hormone injections 6 times/week. Hypertension requiring medical therapy developed in patient 21, 3 weeks after initiation of octreotide therapy. Extensive workup for organic causes of hypertension was negative. Hypertension was resolved 2 weeks after discontinuation of octreotide therapy.

DISCUSSION

Octreotide alters multiple aspects of gastrointestinal physiology and is a valuable therapeutic addition in the treatment of a variety of gastrointestinal disorders. In adults, octreotide therapy worked in the management of variceal hemorrhage, secretory diarrhea and profound excessive ileostomy losses, gastroenteropancreatic tumors, dumping syndrome, pancreatic and enterocutaneous fistulas, and pancreatitis. Although experience with octreotide is more limited in pediatrics, our data indicate that octreotide is extremely useful to treat several gastrointestinal disorders that remain difficult to manage in children.

Octreotide significantly reduced the amount of blood transfusions in children with severe gastrointestinal bleeding and hemodynamic instability. Because of its potential to reduce portal blood flow, hepatic venous pressure gradient and ayzyos blood flow, the effectiveness of octreotide in controlling upper gastrointestinal bleed in adults has been largely reported in cases of variceal hemorrhage secondary to portal hypertension. In this study, 87% of responders had portal hypertension-induced bleeding lesions and octreotide therapy allowed them to be managed with banding or sclerotherapy after hemodynamic stabilization. Randomized controlled trials in adults demonstrate that a combination of endoscopic sclerotherapy/banding and octreotide is more effective than sclerotherapy or banding done alone in controlling acute variceal bleeding and preventing early rebleeding episodes. Although octreotide dose for acute variceal hemorrhage is well established in adults with 50–100 µg IV bolus followed by continuous infusion at 25–50 µg/h, no pediatric dose has been tested. From results in this study and other pediatric case series, it seems that 1–2 µg/kg bolus followed by a continuous infusion of 1–2 µg/kg/h for 2–5 days is effective and safe. No data indicate that a higher dose or longer duration is more effective and free of adverse effects. Higher octreotide dose in patient 7 and longer duration of therapy in patient 10 were associated with major adverse effects.

While the role of octreotide in the treatment of nonvariceal gastrointestinal mucosal lesions is not well established, it has been successfully used to treat severe nonvariceal bleeding in adults and children. Octreotide successfully reduced bleeding in a patient with typhlitis and cecal ulceration prior to surgery. Octreotide failed to control massive bleeding in a child with a Meckel’s diverticulum, Non-steroidal anti-inflammatory drug induced bleeding in chronic renal failure or in a child with hepatic failure induced coagulopathy. The available data from randomized controlled trials in adults, about the efficacy of octreotide in controlling bleeding peptic ulcers are controversial. Octreotide may reduce massive Gastrointestinal bleeding in patients with unknown and potentially treatable causes of bleeding while diagnostic and therapeutic maneuvers are being conducted. It is not a substitute for definitive therapy in these situations.

Historically, pediatric pancreatic pseudocysts have been treated with operative or percutaneous drainage procedures, and occasionally with conservative management. In our study, the use of octreotide has successfully resulted in complete resolution of the pseudocysts over a mean of 15 days, thereby preventing surgery and facilitating wean of TPN. Similar results have been obtained in 4 pediatric case reports. Pancreatic fistula and ascites result from pancreatic ductal disruption with subsequent leakage of pancreatic juice. Octreotide inhibited pancreatic secretions and allowed healing of pancreatic duct with the resolution of ascites in 2 of our patients and in a case report. Although the published adult data on the use of octreotide in the treatment of acute pancreatitis are disappointing, octreotide dramatically decreased serum lipase levels in all 4 patients and facilitated withdrawal of morphine in patient 13 with good control of pain. Octreotide was used to relieve severe pain associated with chronic pancreatitis perhaps by decreasing intraductal pressure caused by pancreatic secretions. In multicenter controlled therapeutic trials, somatostatin significantly reduced serum lipase levels and reduced the clinical need for analgesics. However, it did not reduce mortality. So although there may be benefit in
administering octreotide in cases of severe pancreatitis, the substantial number of studies in which no benefit could be demonstrated should also be noted. Diverse therapeutic methods were used and this may be one of the main reasons for the inconsistency of the results.

Somatostatin inhibits pancreatic secretion in a dose-dependent way. Pseudocysts in our patients resolved at different time intervals after initiation of octreotide in an inverse relation to the dose of octreotide used. Other pediatric case reports support this observation. A lower SC dose of octreotide (2.5 µg/kg/d) that is similar to the octreotide dose used in patient 15, led to resolution of similarly sized pancreatic pseudocysts in 2 children in 4 weeks. At higher doses, 10.5 and 7.5 µg/kg/d, we achieved complete resolution of pseudocysts in patients 12 and 14, respectively, over a shorter time (10–14 days). A continuous IV infusion of octreotide at 1 µg/kg/h was associated with clinical improvement in 3 children with acute pancreatitis.

In adults, SC doses of octreotide at 100, 250, and 500 µg three times daily (TID) were used with clinical benefit. The minimal effective dosage of octreotide remains to be determined. Low doses may be not sufficient, yet high doses decrease splanchnic blood flow and pancreatic perfusion, which could be associated with aggravation of pancreatitis. Octreotide has excellent bioavailability after SC administration and is the preferred mode of therapy for the prolonged treatment. However, IV route may be advantageous for acutely ill patients with hypovolemia and circulatory failure when SC absorption of drugs is suboptimal. For the management of complications of pancreatitis, an initial SC dose of 7.5 µg/kg/d divided TID is recommended.

Chylothorax may have deleterious effects on the immunologic and nutritional status of patients. Standard management of chylothorax includes medium chain triglyceride-based feeds, bowel rest with TPN, and surgical intervention, in the form of thoracic duct ligation, pleurodesis or placement of pleuropertitoneal shunt, if medical treatment fails. Such an approach has been associated with significant morbidity, prolonged hospitalization and mortality. Data from our study and case reports in children indicate that octreotide can treat chylothorax as evidenced by shortening of TPN duration, hospital stay, and avoiding surgery. The mechanism of action of octreotide is not understood. Octreotide may reduce thoracic duct lymph flow or may act on somatostatin receptors in the splanchnic circulation to reduce lymph fluid absorption. Our mean octreotide dose, 10 µg/kg/d divided b.i.d. SC, was used by others with good results. A continuous IV infusion of octreotide at 1–3.5 µg/kg/hr also was effective.

Octreotide is effective in reducing stool output in children with a variety of disorders, including massive ileostomy loss, intestinal fistula, congenital microvillus atrophy, idiopathic secretory diarrhea, carcinoid tumour, cryptosporidium diarrhea and watery diarrhea hypokalemia achlorhydria syndrome. The precise mechanisms by which octreotide exerts its beneficial effect is uncertain. Some studies demonstrated normal gastrointestinal hormonal secretions throughout octreotide therapy, suggesting that the effect of octreotide on stool losses was likely due to the direct inhibition of intestinal secretion and increased intestinal fluid absorption. In two children in this case series, stool losses were reduced by 78% and 59% at 3 months post-initiation of octreotide at doses ranging from 8 to 60 µg/kg/d SC divided either b.i.d. or t.i.d. The decrease in stool output was accompanied by tolerance of increasing volumes of enteral feeds and parallel reduction of TPN while maintaining good weight gain. As a consequence, both patients remained free of TPN-associated cholestasis. In the literature, multiple doses of octreotide were used, ranging from 3.8 to 34.6 µg/kg/d SC b.i.d. or t.i.d. for a variable length of time.

In adults, octreotide has been proposed as a possible therapeutic agent in patients with dumping syndrome, with doses ranging from 50 to 100 µg b.i.d–q.i.d. SC 15 to 30 min before meals. Its therapeutic benefit probably relates both to slowing of gastric emptying, increasing small bowel transit time and inhibiting the release of mediators of the vasomotor symptoms. Our patient is the first pediatric case with successful use of octreotide in dumping syndrome. Octreotide before meals appears to be promising in children with dumping syndrome unresponsive to continuous enteral feed and dietary modification.

Four of 21 patients suffered significant adverse effects. Q–T interval prolongation is an extremely rare adverse effect of octreotide. A high octreotide infusion rate (4 µg/kg/h) in patient 7 with probable pre-existing congenital Q–T prolongation might have well triggered the development of bradycardia and cardiac arrhythmia, which are rare side effects of octreotide. Octreotide should be avoided in patients with diagnosed or suspected congenital long Q–Tc syndrome and cautiously used in conjunction with drugs that prolong Q–T interval. Electric cardiography prior to initiation of octreotide therapy is strongly indicated. Prolonged use of octreotide (>14 days) in patients 10, 20, and 21 was a possible determining factor in the development of adverse effects in these patients. In patient 21, a lack of other possible causes of hypertension and normalization of blood pressure after discontinuation of octreotide, make octreotide the most likely cause of hypertension, another recognised cardiovascular effect of octreotide. Therefore, regular check of blood pressure is recommended during octreotide therapy. Because of its inhibitory action on insulin,
octreotide has been associated with glucose intolerance and hyperglycemia that may necessitate insulin therapy. This indicates close monitoring of blood glucose during octreotide therapy. In adults, octreotide has been frequently used in the treatment of acromegaly, due to its inhibitory actions on growth hormone and insulin-like growth factor 1 secretion. Growth hormone level was suppressed in 2 children treated with octreotide for 3–4 weeks. The concern that octreotide may cause growth retardation on long-term use has been refuted by several studies. The development of symptomatic growth hormone deficiency in patient 20 indicates that close monitoring of growth hormone level and growth velocity would be required. None of our patients developed cholelithiasis, a complication reported in long-term users of octreotide.

**CONCLUSION**

In conclusion, although our study is retrospective and uncontrolled, it indicates that octreotide provides a valuable addition to the therapeutic armamentarium of the pediatric gastroenterologists for a wide variety of disorders. Large prospective, placebo-controlled and multicenter trials are needed to determine octreotide pharmacokinetics, therapeutic doses and clinical efficacy in children. Serious adverse events may occur at high doses or long-term use of octreotide and patients must be closely monitored.

**REFERENCES**

1. Gyr KE, Meier R. Pharmacodynamic effects of Sandostatin in the gastrointestinal tract. Digestion 1993;54(Suppl 1):14-9.
2. Lucey MR, Yamada T. Biochemistry and physiology of gastrointestinal somatostatin. Dig Dis Sci 1989;34(3 Suppl):55-13S.
3. Whitehouse I, Beglinger C, Ruttimann G, Gyr K. Inhibition of pentagastrin-stimulated acid secretion after subcutaneous administration of a new somatostatin analogue. Gut 1986;27:141-6.
4. Polak JM, Broom SR. Somatostatin localisation in tissues. Scand J Gastroenterol Suppl 1986;119:11-21.
5. Kraenzlin ME, Wood SM, Neufeld M, Adrian TE, Bloom SR. Effect of long acting somatostatin-analogue, SMS 201-995, on gut hormone secretion in normal subjects. Experientia 1985;41:738-40.
6. Lembcke B, Creutzfeldt W, Schleser S, Ebert R, Shaw C, Koop I. Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Digestion 1987;36:108-24.
7. Tauber MT, Harris AG, Rochiccioli P. Clinical use of the long acting somatostatin analogue octreotide in pediatrics. J Pediatr 1994;153:304-10.
8. Heikinen JB, Pohl JF, Werlin SJ, Bucuvalas JC. Octreotide in pediatric patients. J Pediatr Gastroenterol Nutr 2002;35:600-9.
9. Eroglu Y, Emerick KM, Whittington PF, Alonso EM. Octreotide therapy for control of acute gastrointestinal bleeding in children. J Pediatr Gastroenterol Nutr 2004;38:41-7.
10. Grosman I, Simon D. Potential gastrointestinal uses of somatostatin and its synthetic analogue octreotide. Am J Gastroenterol 1990;85:1061-71.
11. Mosdell KW, Visconti JA. Emerging indications for octreotide therapy, Part 1. Am J Hosp Pharm 1994;51:1184-92.
12. Hadengue A. Somatostatin or octreotide in acute variceal bleeding. Digestion 1999;60 (Suppl 2):31-41.
13. McCormick PA, Dick R, Siringo S. Octreotide reduces ayous blood flow in cirrhotic patients with portal hypertension. Eur J Gastroenterol Hepatol 1990;2:489-92.
14. Hwang SJ, Lin HC, Chang CF, Lee FY, Lu CW, Hsia HC. et al. A randomized controlled trial comparing octreotide and vasopressin in the control of acute oesophageal bleeding. J Hepatol 1992;16:320-5.
15. Besson I, Ingrand P, Person B, Boutroux D, Heresbach D, Bernard P, et al. Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med 1995;333:555-60.
16. Sung JH, Chung SC, Yung MY, Lai CW, Lau JY, Lee YT. et al. Prospective randomised study of effect of octreotide in rebleeding from oesophageal varices after endoscopic ligation. Lancet 1995;346:1666-9.
17. Sadowski DC. Use of octreotide in the acute management of bleeding oesophageal varices. Can J Gastroenterol 1997;11:339-43.
18. Siafakas C, Fox VL, Nurko S. Use of octreotide for the treatment of severe gastrointestinal bleeding in children. J Pediatr Gastroenterol Nutr 1998;26:356-9.
19. Jenkins SA, Taylor BA, Nott DM, Ellenbogen S, Haggie J, Shields R. Management of massive gastrointestinal haemorrhage from multiple sites of peptic ulceration with somatostatin and octreotide - A report of five cases. Gut 1992;33:404-7.
20. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996;334:246-54.
21. Nikolopoulou VN, Thomopoulos KC, Katsakouli ES, Vasiopouloa AG, Margaritis VG, Vagianos CE. The effect of octreotide as an adjunct treatment in active nonvariceal upper gastrointestinal bleeding, J Clin Gastroenterol 2004;38:243-7.
22. Christiansen J, Ottenjann R, Van Arx F. Placebo-controlled trial with the somatostatin analogue SMS 201-995 in peptic ulcer bleeding. Gastroenterology 1989;97:568-74.
23. Lin HJ, Perng CL, Wang K, Lee CH, Lee SD. Octreotide for arrest of peptic ulcer haemorrhage – a prospective, randomized controlled trial. Hepatogastroenterology 1995;42:856-60.
24. Mulligan C, Howell C, Hatley R, Martindale R, Clark J. Conservative management of pediatric pancreatic pseudocyst using octreotide acetate. Am Surg 1995;61:206-9.
25. Bosman-Vermeeren JM, Veereman-Wauters G, Broos P, Eggemant E. Somatostatin in the treatment of pancreatic pseudocyst in a child. J Pediatr Gastroenterol Nutr 1996;23:422-5.
26. Tissieres P, Bugmann P, Rimensberger PC, Mentha G, Lencourte C, Belli DC. Somatostatin in the treatment of pancreatic pseudocyst complicating acute pancreatitis in a child with liver transplantation. J Pediatr Gastroenterol Nutr 2000;31:445-7.
27. Rushforth JA, Beck JM, McMahon M, Puntis JW. Resolution of pancreatic ascites with octreotide. Arch Dis Child 1993;68:135-6.
28. Cavallini G, Frulloni L. Somatostatin and octreotide in acute pancreatitis: the never-ending story. Dig Liver Dis 2001;33:192-201.
29. Greenberg R, Haddad R, Kashtan H, Kaplan O. The effects of somatostatin and octreotide on experimental and human acute pancreatitis. J Lab Clin Med 2000;135:112-21.
30. Malfertheiner P, Mayer D, Buchler M, Domínguez-Munoz JE, Schiefer B, Ditschuneit H. Treatment of pain in chronic pancreatitis by inhibition of pancreatic secretion with octreotide. Gut 1995;36:450-4.
31. Usadel KH, Uberla KK, Leuschner U. Treatment of acute pancreatitis with somatostatin. Results of a multi-center double-blind trial (APTS-Study). Dig Dis Sci 1985;30:992.
32. D’Amico D, Favia G, Biasiato R, Casaccia M, Falcone F, Fersini M, et al. The use of somatostatin in acute pancreatitis: Results of a multi-center...
33. Choi TK, Mok F, Zhan WH, Fan ST, Lai ECS, Wong J. Somatostatin in the treatment of acute pancreatitis: a prospective randomised controlled trial. Gut 1989;30:223-7.

34. Gullo L, Priori P, Scarpignato C, Baldoni F, Mattioli G, Barbara L. Effect of somatostatin 14 on pure human pancreatic secretion. Dig Dis Sci 1987;32:1065-70.

35. Lam JC, Aters S, Tobias JD. Initial experience with octreotide in the pediatric population. Am J Ther 2001;8:409-15.

36. Paran H, Neufeld D, Mayo A, Shwartz I, Singer P, Kaplan O, et al. Preliminary report of a prospective study in the treatment of severe acute pancreatitis. J Am Coll Surg 1995;181:121-4.

37. Binder M, Uhl W, Fries W, Malferttheiner P, Bachler MW. Octreotide in the treatment of acute pancreatitis: results of a unicentric prospective trial with three different octreotide dosages. Digestion 1994;55 Suppl 1:20-3.

38. Conway DR, Djuricin G, Prinz RA. The effect of somatostatin analogue (SMS 201-995) on pancreatic blood flow. Surgery 1988;104:1024-30.

39. Klar E, Rattner DW, Compton C, Stanford G, Chernow B, Warshow AL. Adverse effect of vascular gas-constrictors in experimental acute pancreatitis. Ann Surg 1991;214:168-74.

40. Beghetti M, La Scala G, Belli D, Bugmann P, Kalangos A, Le Coultre C. Etiology and management of pediatric chylolymphaticias. J Pediatr Gastroenterol Nutr 1998;27:1359-65.

41. DeLedinghen V, Ripault MP, Silvain C, Beauchant M, Rauchoux N, Bouquet S. Subcutaneous octreotide for the prevention of early variceal bleeding. Hepatology 1996;23:938-39.

42. Cerfolio RJ, Allen MS, Deschamps C, Trastek VF, Pairolero PC. Postoperative chylothorax. J Thorac Cardiovasc Surg 1996;112:1361-6; discussion 1365-6.

43. Browse NL, Wilson NM, Russo F, al-Hassan H, Allen DR. Aetiology and treatment of chylous ascites. Br J Surg 1992;79:1145-50.

44. Rosti L, Bini RM, Chessa M, Butera G, Drago M, Carminati M. The effectiveness of octreotide in the treatment of post-operative chylorrhaces. Eur J Pediatr 2002;161:149-50.

45. Cheung Y, Leung MP, Yip M. Octreotide for treatment of post-operative thoracic duct lymph in normal and vagotomized dogs. Diabetes 1987;36:120-3.

46. Petersen JM, Saltzman M, Sherwin RS, Lange R, McCallum RW. Somatostatin inhibits gastric emptying of solids and liquids in man (Abstract) Dig Dis Sci 1984;29:A64.

47. DeClue TJ, Malone JI, Bercu BB, et al. Watery diarrhea, hypokalemia, achlorhydria syndrome in an infant: effect of the long-acting somatostatin analogue SMS 201-995 on the disease and linear growth. J Pediatr Gastroenterol Nutr 1987;6:710-16.

48. Geer RJ, Richards WO, O'Dorisio TM, Woltering EO, Williams S, Rice D, et al. Efficacy of octreotide acetate in treatment of severe postgastrectomy dumping syndrome. Ann Surg 1990;212:678-87.

49. Hopman WP, Wolberink KG, Lamers CB, Van Tongeren JH. Treatment of the dumping syndrome with the somatostatin analogue SMS 201-995. Ann Surg 1988;207:155-9.

50. Primrose JN, Johnston D. Somatostatin analogue SMS 201-995 (octreotide) as a possible solution to the dumping syndrome after gastrectomy or vagotomy. Br J Surg 1989;76:140-4.

51. Petersen JM, Saltzman M, Sherwin RS, Lange R, McCallum RW. Somatostatin inhibits gastric emptying of solids and liquids in man (Abstract) Dig Dis Sci 1984;29:A64.

52. Hasler WL, Soudah HC, Owoyanga C. Mechanisms by which octreotide ameliorates symptoms in the dumping syndrome. J Pharmacol Exp Ther 1996;277:1359-65.

53. Fatti LM, Scachci M, Lavezezi E, Pecori Giraldi F, De Martin M, Toja P, et al. Efficacy of treatment with somatostatin analogues on QT interval duration in acromegalic patients. Clin Endocrinol (Oxf). 2006;65:626-30.

54. Herrington AM, George KW, Moulds CC. Octreotide-induced bradycardia. Pharmacotherapy 1998;18:413-6.

55. Battershill PE, Clezzold SP. Octreotide: A review of its pharmacokinetic properties and therapeutic potential in conditions associated with excessive peptide secretion. Drugs 1989;38:658-702.

56. DeClue TJ, Malone JI, Bercu BB. Linear growth during long-term treatment with somatostatin analogue (SMS 201-995) for persistent hyperinsulinemic hypoglycemia of infancy. J Pediatr 1990;116:747-50.

57. Glaser B, Landau H, Smilovic A, Nesher R. Persistent hyperinsulinaemic hypoglycaemia of infancy: long-term treatment with the somatostatin analogue Sandostatin. Clin Endocrinol 1989;31:71-80.

58. Dowling RH, Hussaini SH, Murphy GM, Besser GM, Wass JA. Gallstones during octreotide therapy. Metabolism 1992;41(9 Suppl 2):22-33.

Source of Support: Nil, Conflict of Interest: None declared.